Clinical Research Directory
Browse clinical research sites, groups, and studies.
MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD
Sponsor: Capital Medical University
Summary
This randomized controlled trial will investigate the clinical impact of Myxovirus Resistance A (MxA) and C-Reactive Protein (CRP)-guided antimicrobial treatment compared to usual care in outpatients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Official title: Myxovirus Resistance Protein a and C-Reactive Protein-Guided Antimicrobial Treatment in Outpatients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
458
Start Date
2025-01-13
Completion Date
2026-12-31
Last Updated
2025-01-16
Healthy Volunteers
No
Interventions
MxA and CRP tests
A whole blood sample will be collected on the day of randomization for MxA and CRP testing.
MxA and CRP feedback
MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.
Follow up
Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization. Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score). Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death.
Locations (1)
China-Japan Friendship hospital
Beijing, Beijing Municipality, China